Skip to main content
. 2021 Dec 20;23(2):e53865. doi: 10.15252/embr.202153865

Figure 2. Biparatopic Nanobodies target several recently identified RBD variants with picomolar affinity.

Figure 2

  • A–P
    Affinity measurements by BLI of bipNb NM1267 and NM1268 on recently identified RBD variants B.1.1.7 (Alpha) (A, I), B.1.351 (Beta) (B, J), P1 (Gamma) (C, K), B.1.617.2 (Delta) (D, L), B.1.429 (Epsilon) (E, M), P3 (Theta) (F, N), B.1.617.1 (Kappa) (G, O), and A.23.1 (H, P). NM1267 and NM1268 were applied with concentrations ranging from 5 to 0.625 nM and from 20 to 2.5 nM, respectively (illustrated with gradually lighter shades), on immobilized RBD variants. Global 1:1 fits are illustrated as dashed lines.
  • Q
    Tabular summary of binding affinity (K D), association (k on), and dissociation constant (k off) determined for the individual RBD variants.